Pharsight

Kazano generic

Kazano is an anti-diabetic drug owned by Takeda Pharmaceuticals USA and was first approved for market use on 25 January 2013. It is available in tablet form for oral administration. Kazano's active ingredients are Alogliptin Benzoate and Metformin Hydrochloride. The drug has a total of 4 patents.

When will Kazano generic be available?

The release of Kazano's generic versions is not expected until after 24 May 2029. This estimation is based on the expiry date of the last patent, titled 'Solid preparation comprising alogliptin and metformin hydrochloride'. The other three patents, all titled 'Dipeptidyl peptidase inhibitors', will expire on 2025-03-15, 2025-06-24, and 2028-06-27, respectively. The extended date for the release of Kazano generic is a result of the Para IV filing, a type of patent challenge filed by generic manufacturers.

Kazano uses

Kazano is used for the treatment of diabetes. It works mainly by administering Alogliptin, a dipeptidyl peptidase inhibitor, which is effective in controlling high blood sugar levels in patients with type 2 diabetes.

Kazano patent expiration

Kazano holds 4 patents, with the last one (US8900638, titled 'Solid preparation comprising alogliptin and metformin hydrochloride') expiring on 24 May 2029. This will allow the introduction of Kazano generic into the market. A summary of the patents related to Kazano is given below:

Kazano dosage

Want to ask something?